Schoening Wenzel, Helbig Michael, Buescher Niklas, Andreou Andreas, Schmitz Volker, Bahra Marcus, Puhl Gero, Pascher Andreas, Pratschke Johann, Seehofer Daniel
Department of General, Visceral- and Transplantation Surgery, Charité, Berlin, Germany.
Department of General-, Visceral- and Transplantation Surgery, University Hospital of RWTH Aachen, Germany.
Clin Transplant. 2016 May;30(5):508-17. doi: 10.1111/ctr.12714. Epub 2016 Mar 16.
The organ shortage has led to increased use of marginal organs. The Eurotransplant Donor-Risk-Index (ET-DRI) was established to estimate outcome after Liver Transplantation (LT). Currently, data on impact of ET-DRI on long-term outcome for different indications and recipient conditions are missing. Retrospective, single-center analysis of long-term graft survival (GS) of 1767 adult primary LTs according to indication, labMELDcategory (1: ≤18; 2: >18-25; 3: >25-35; 4: >35), and ET-DRI. Mean ET-DRI in our cohort was 1.63 (±0.43). One-, 10, and 15-yr GS was 83.5%, 63.3%, and 54.8%. Long-term GS was significantly influenced by ET-DRI. Accordingly, four ET-DRI categories were defined and analyzed with respect to underlying disease. Significant impact of these categories was observed for: Alcohol, cholestatic/autoimmune diseases (CD/AIH), and HCV, but not for HCC, HBV, cryptogenic cirrhosis, and acute liver failure. labMELD categories showed no significant influence on graft, but on patient survival. Matching ET-DRI categories with labMELD revealed significant differences in long-term GS for labMELDcategories 1, 2, and 3, but not 4. In multivariate analysis, HCV combined with ET-DRI > 2 and labMELDcategory 3 combined with ET-DRI > 2 emerged as negative predictors. To achieve excellent long-term graft survival, higher risk organs (ET-DRI > 1.4) should be used restrictively for patients with CD/AIH or HCV. Organs with ET-DRI > 2 should be avoided in patients with a labMELD of >25-35.
器官短缺导致边缘器官的使用增加。欧洲移植供体风险指数(ET-DRI)旨在评估肝移植(LT)后的预后。目前,关于ET-DRI对不同适应证和受者情况的长期预后影响的数据尚缺。对1767例成人初次LT患者的长期移植物存活(GS)进行回顾性单中心分析,分析指标包括适应证、实验室MELD分类(1:≤18;2:>18-25;3:>25-35;4:>35)以及ET-DRI。我们队列中的平均ET-DRI为1.63(±0.43)。1年、10年和15年的GS分别为83.5%、63.3%和54.8%。长期GS受ET-DRI的显著影响。因此,定义了四个ET-DRI类别,并针对基础疾病进行分析。观察到这些类别对以下疾病有显著影响:酒精性、胆汁淤积性/自身免疫性疾病(CD/AIH)和丙型肝炎病毒(HCV)感染,但对肝细胞癌(HCC)、乙型肝炎病毒(HBV)感染、隐源性肝硬化和急性肝衰竭无显著影响。实验室MELD分类对移植物无显著影响,但对患者生存有影响。将ET-DRI类别与实验室MELD分类相匹配,发现实验室MELD分类1、2和3在长期GS方面存在显著差异,但分类4无差异。多因素分析显示,HCV合并ET-DRI>2以及实验室MELD分类3合并ET-DRI>2是阴性预测因素。为实现优异的长期移植物存活,对于CD/AIH或HCV患者,应限制使用高风险器官(ET-DRI>1.4)。对于实验室MELD>25-35的患者,应避免使用ET-DRI>2的器官。